AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27250881
Drug: 3 weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 weekly cisplatin (100 mg/m2, 3 cycles)
Trial: 19948879
Drug: Low-dose deferoxamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose deferoxamine (2.5 mg/kg/week)
Trial: 19948879
Drug: Standard-dose deferoxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose deferoxamine (5 mg/kg/week)
Trial: 18608737
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg for 3 consecutive days, administered in three monthly pulses
Trial: 15950634
Drug: TNF‐alpha plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐alpha plus infliximab (400 microg/mL)
Trial: 10582984
Drug: IV/IA r-TPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/IA r-TPA therapy
Trial: 10582984
Drug: Placebo/IA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/IA therapy
Trial: 6140702
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from long-term benzodiazepine treatment
Trial: 29845639
Drug: Benzocaine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine at 60, 85, 110, 135, and 160 mg/L
Trial: 29845639
Drug: Eugenol at
RxNorm normalized name: Eugenol
DrugBank: Eugenol (DB09086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eugenol at 40, 80, 120, 160, and 200 mg/L
Trial: 29845639
Drug: Menthol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol at 50, 75, 150, 200, and 250 mg/L
Trial: 21395142
Drug: Intravenous amiodarone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone, 6 mg/kg/day
Trial: 21395142
Drug: Oral propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propafenone, 6.6 mg/kg/day
Trial: 10354124
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous heparin infusion
Trial: 1702569
Drug: Amiksin (0.125-0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiksin (0.125-0.25 g orally)
Trial: 1702569
Drug: Amiksin (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiksin (1-2 tablets at least 2 days apart)
Trial: 7460760
Drug: Methadone/methadyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone/methadyl acetate treatment
Trial: 22720766
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed fluoxetine treatment (once-weekly for 24 weeks, then self-administered for 12 weeks)
Trial: 19885996
Drug: Cort80 (6.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cort80 (6.3 mg/hr/70 kg)
Trial: 19885996
Drug: Cort160 (12.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cort160 (12.6 mg/hr/70 kg)
Trial: 17760727
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment with amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 20 mg b.i.d. for 14 days in patients with positive (13)C-UBT.
Trial: 17760727
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no H. pylori eradication treatment).
Trial: 15172264
Drug: Preoperative intraaortic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative intraaortic balloon pump (IABP) therapy
Trial: 9725756
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 mg oral)
Trial: 9065553
Drug: IVIg (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (2 g/kg intravenous immunoglobulin)
Trial: 1775594
Drug: d‐ala‐Peptide‐T‐amide (Peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐ala‐Peptide‐T‐amide (Peptide T) intravenous administration at doses ranging from 0.1 to 3.2 mg/kg/day for 12 weeks
Trial: 1775594
Drug: Intranasal Peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Peptide T at 25 mg/day for 8 weeks after a 4-week off-drug period
Trial: 1775594
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (no drug administration)
Trial: 7046652
Drug: Rifamycin SV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifamycin SV, 500 mg weekly
Trial: 7046652
Drug: Saline solution,
RxNorm normalized name: Sterile Saline Solution, Contact Lens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution, 10 ml
Trial: 23301471
Drug: Acupoint embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint embedding therapy
Trial: 26511489
Drug: Glucoraphanin (GFN)
RxNorm normalized name: Guaifenesin
DrugBank: Glucoraphanin (DB15436)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucoraphanin (GFN) supplement providing Sulforaphane (SFN)
Trial: 1438647
Drug: Imipramine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (1 mg/kg)
Trial: 4026972
Drug: Ethanol infusion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol infusion to reach blood alcohol concentration of 1 mg/ml in 1 hr
Trial: 4026972
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (control)
Trial: 18807574
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of dental implants (20 implants)
Trial: 18807574
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of dental implants (20 implants)
Trial: 10716066
Drug: Intranasal 17-beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17-beta-estradiol (300 microg)
Trial: 10716066
Drug: Reservoir patch
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reservoir patch (50 microg/day of 17-beta-estradiol)
Trial: 10716066
Drug: Tablet (2
RxNorm normalized name: VOYDEYA Tablet (200mg Dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (2 mg micronised 17-beta-estradiol)
Trial: 8538478
Drug: Menorest 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest 50 twice weekly for 12 weeks
Trial: 8538478
Drug: Premarin 0.625
RxNorm normalized name: Premarin 0.625mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 0.625 mg daily for 12 weeks
Trial: 1985041
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment (psychotherapy, relaxation, and standard medical treatment)
Trial: 26817916
Drug: Tumor differentiation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor differentiation, postoperative chemotherapy, and pre-MSH6 expression
Trial: 24534207
Drug: αTMS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: αTMS treatment group
Trial: 21392832
Drug: Bone Marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone Marrow Stem Cells (BMSC) intracoronary infusion
Trial: 17567869
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg 3 times daily for 4 weeks
Trial: 12745558
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg vitamin C twice daily until 34 weeks' gestation
Trial: 16368577
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo twice daily until 34 weeks' gestation
Trial: 12501129
Drug: NVP increased
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP increased from 400 mg/day to 600 mg/day
Trial: 12501129
Drug: Standard NVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard NVP dosing (400 mg/day)
Trial: 7814752
Drug: Beta 1‐adrenolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1‐adrenolytic agent
Trial: 7814752
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no adrenolytic agents)
Trial: 7814752
Drug: Alpha 1‐adrenolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha 1‐adrenolytic agent
Trial: 31894993
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacotherapy
Trial: 15777891
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral iron therapy of 100 mg of elemental iron
Trial: 15777891
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of iron sorbitol intramuscularly, repeated at an interval of 4‐6 weeks
Trial: 27918586
Drug: Multiple Micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Micronutrient (MM) supplements (15 micronutrients with similar amounts of IFA)
Trial: 27918586
Drug: Iron-Folic Acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-Folic Acid (IFA) supplements (60 mg Fe and 2800 μg FA)
Trial: 27918586
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2800 μg FA)
Trial: 22192331
Drug: Der p-SIT
RxNorm normalized name: Diäthylaminoäthanol ester der p-butylaminobenzösäure
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Der p-SIT + pharmacotherapy
Trial: 1778354
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment and/or increase of physical activity or training
Trial: 6954092
Drug: Pressurized aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pressurized aerosol salbutamol (0.1-2.4 mg)
Trial: 6954092
Drug: Powder aerosol
RxNorm normalized name: Aluminum Chlorohydrate 8.8 g in 100 g TOPICAL AEROSOL, SPRAY [SUAVE POWDER AEROSOL ANTIPERSPIRANT AND DEODORANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder aerosol salbutamol (0.2-4.8 mg)
Trial: 28650331
Drug: Th17 cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th17 cells and CD4+ CD25+ Foxp3+ cells after 6 months of chemotherapy
Trial: 28650331
Drug: Serum IL‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL‐17 and TGF‐β levels after 6 months of chemotherapy
Trial: 25738177
Drug: 5 mm
RxNorm normalized name: SUR-FIT 45 mm Wafer, Small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mm implants
Trial: 25738177
Drug: 11.5 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.5 mm implants
Trial: 25738177
Drug: Long maxillary
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long maxillary implants
Trial: 25738177
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of short vs long implants
Trial: 17445287
Drug: Anticonvulsant withdrawal
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant withdrawal
Trial: 15910687
Drug: Heberitro (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heberitro (formulation A)
Trial: 15910687
Drug: Eprex (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprex (formulation B)
Trial: 15235998
Drug: 0.25% or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% or 0.5% bupivacaine at a rate of 3‐7 ml.hr(‐1)
Trial: 15235998
Drug: 0.01% morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% morphine at a rate of 1‐2 ml.hr(‐1)
Trial: 28358452
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg isobaric levobupivacaine
Trial: 28358452
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg isobaric bupivacaine
Trial: 21136268
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia (IA)
Trial: 9535992
Drug: EM574 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EM574 5 mg
Trial: 9535992
Drug: EM574 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EM574 10 mg
Trial: 9535992
Drug: EM574 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EM574 20 mg
Trial: 9535992
Drug: EM574 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EM574 30 mg
Trial: 3189965
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (MgSO4) 2 grams administered IV for 20 minutes (0.40 mmol/min)
Trial: 3189965
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (control) administered IV for 20 minutes
Trial: 15800308
Drug: Amifostine (AM)
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine (AM) 500 mg IV four times per week
Trial: 17087311
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with folic acid, vitamin B12, and B6
Trial: 17087311
Drug: Vitamin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin treatment for reduction of hyperhomocysteinemia
Trial: 12544649
Drug: Glycerol hyperhydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol hyperhydration (1.0 g.kg(-1))
Trial: 12544649
Drug: Glycerol rehydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol rehydration (0.5 g.kg(-1))
Trial: 9709312
Drug: Oral airway/Bag-Valve-Mask
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral airway/Bag-Valve-Mask (OA/BVM) system
Trial: 29776899
Drug: Group exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group exercise intervention using videoconferencing and mobile apps (e.g., Nike+, Sworkit) for 8 weeks.
Trial: 23369067
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus craniosacral therapy
Trial: 8526828
Drug: Dexedrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexedrine (10 mg)
Trial: 8602776
Drug: Krypton red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton red laser photocoagulation treatment for classic CNV
Trial: 8602776
Drug: Krypton red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton red laser photocoagulation treatment for classic and occult CNV
Trial: 8602776
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for eyes with occult CNV but no classic CNV
Trial: 1384762
Drug: GIK group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK group (glucose, 0.6 g/kg/h; insulin, 0.12 U/kg/h; KCl, 0.12 mmol/kg/h)
Trial: 2579598
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg t.i.d., 48 h prior to and up to 24 h following challenge with anti-IgE 1/3300 (v/v)
Trial: 2579598
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg, b.i.d.
Trial: 2579598
Drug: Indomethacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (oral and i.d.)
Trial: 28624167
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide Implant
Trial: 28624167
Drug: Systemic Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Corticosteroid Therapy
Trial: 28624167
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide Implant (for individuals with initial visual acuity worse than 20/40)
Trial: 8727452
Drug: MedX lumbar‐extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedX lumbar‐extension machine, isotonic exercises two times per week, reduced to one time per week, average length of treatment 97 days and 20 visits.
Trial: 6405908
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term outpatient treatment programme of eclectic orientation
Trial: 30797646
Drug: Carbohydrate reduced
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate reduced hospital diet (CRD) of 135 g/d
Trial: 22213153
Drug: Enzastaurin (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (loading dose 1125 mg, followed by 500 mg/d) with 5-fluorouracil/leucovorin plus bevacizumab
Trial: 18306904
Drug: Methylprednisolone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (16 mg/die for the first 7 days, then 8 mg die for another 7 days, and finally 4 mg die for another 7 days) plus conventional therapy (bronchodilators and inhaled corticosteroids)
Trial: 12100834
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) support intervention
Trial: 18042668
Drug: Tyrosine supplementation
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine supplementation (graded intakes from 2.5 to 12.5 mg.kg(‐1).day(‐1))
Trial: 12442931
Drug: Sufentanil 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 8 mL bolus, followed by infusion at 5 mL h(‐1) of a mixture containing sufentanil 1 microg mL(‐1) and bupivacaine 1 mg mL(‐1)
Trial: 12442931
Drug: Fentanyl 8
RxNorm normalized name: FENTANYL 87.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 8 mL bolus, followed by infusion at 5 mL h(‐1) of a solution containing fentanyl 3.5 microg mL(‐1) and bupivacaine 1 mg mL(‐1)
Trial: 9124784
Drug: Transabdominal preperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transabdominal preperitoneal laparoscopic repair (group L) with 3 x 5 inch polypropylene mesh
Trial: 9124784
Drug: Transabdominal preperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transabdominal preperitoneal laparoscopic repair (group L)
Trial: 6416514
Drug: overnight supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: overnight supplementary nasogastric tube feeding (4.2 MJ (1000 kcal), including 28 g protein) in addition to normal ward diet
Trial: 29701878
Drug: Standard nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutrition care (hourly-rate-based protocol, without protein supplementation)
Trial: 27434221
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor antagonist Exendin 9-39 (Ex-9)
Trial: 19619378
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy (5 sessions over a 5-week period during postoperative radiotherapy)
Trial: 19619378
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no art therapy)
Trial: 18827063
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) in octogenarians
Trial: 18827063
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) in patients <80 years
Trial: 8775472
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus ursodeoxycholic acid (900 mg/day)
Trial: 8775472
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus simvastatin (40 mg/day)
Trial: 2280855
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg/b.i.d./i.v.)
Trial: 2280855
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 UI/t.i.d./s.c.)
Trial: 367678
Drug: Atenolol alone
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol alone (100 mg twice daily)
Trial: 367678
Drug: Atenolol-chlorthalidone combination
RxNorm normalized name: atenolol / chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol-chlorthalidone combination
Trial: 367678
Drug: Atenolol added
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol added to chlorthalidone (100 mg twice daily)
Trial: 367678
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of atenolol
Trial: 27217446
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg intravenously once every 3 weeks)